<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01858311</url>
  </required_header>
  <id_info>
    <org_study_id>2012H0113</org_study_id>
    <nct_id>NCT01858311</nct_id>
  </id_info>
  <brief_title>Nutrition Blood Outcomes Following Tocotrienol N2B</brief_title>
  <acronym>NIIB</acronym>
  <official_title>Human Blood Outcomes Following Tocotrienol Supplementation - Nutrition Phase IIB NUTRITION PHASE IIB</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Malaysia Palm Oil Board</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A natural form of vitamin E called tocotrienol (TCT) has blood thinning and cholesterol&#xD;
      lowering properties, both of which may benefit stroke survivors. This study is being&#xD;
      conducted to determine the blood thinning and cholesterol lowering properties of TCT in&#xD;
      stroke or TIA (transient ischemic attack, which is also referred to as a &quot;mini-stroke&quot;)&#xD;
      survivors that are receiving the standard treatment for prevention of recurrent stroke.&#xD;
&#xD;
      Study Hypothesis: Oral TCT decreases the incidence of aspirin and clopidogrel nonresponders,&#xD;
      increases the extent of inhibition of platelet aggregation, and decreases LDL without&#xD;
      significant side effects in stroke patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this Phase IIB trial the goal is to determine the effects of orally supplemented TCT on&#xD;
      platelet function and cholesterol as well as the safety in patients with TIA (transient&#xD;
      ischemic attack) or stroke in addition to the standard treatment for stroke prevention.&#xD;
      Recurrent cardiovascular events including stroke, TIA, heart attack, venous thrombosis,&#xD;
      pulmonary embolism, systemic embolism will also be recorded. In patients with recurrent&#xD;
      stroke, severity of the stroke and stroke size measured from MR (magnetic resonance) or CT&#xD;
      (computed tomography) imaging will also be collected. We expect that TCT will inhibit blood&#xD;
      clotting and lower cholesterol more than current standard treatment without significantly&#xD;
      increasing bleeding risks or other side effects. Future work is planned in a larger&#xD;
      TIA/stroke population to examine whether TCT adds to standard medical care in terms of&#xD;
      decreasing incidence of stroke and improving outcomes following stroke.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>platelet aggregation activity</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Platelet aggregation activity will be measured using standard clinical laboratory procedures</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of recurrent stroke</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Incidence of recurrent stroke after previous diagnosed stroke or TIA.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">300</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Placebo vehicle</arm_group_label>
    <description>(2) placebo capsules following AM meal and (2) placebo capsules following PM meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tocotrienol capsules (400 mg)</arm_group_label>
    <description>(2) 100mg TCT capsules following AM meal and (2) 100mg TCT capsules following PM meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tocotrienol Capsules (800 mg)</arm_group_label>
    <description>(2) 200mg TCT capsules following AM meal and (2) 200mg TCT capsules following PM meal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Tocotrienol Capsules</intervention_name>
    <description>Vitamin E TCT capsules- 400mg to 800mg per day (2 in the morning and 2 in the evening)</description>
    <arm_group_label>Tocotrienol Capsules (800 mg)</arm_group_label>
    <arm_group_label>Tocotrienol capsules (400 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Vehicle</intervention_name>
    <description>Placebo capsules per day (2 in the morning and 2 in the evening)</description>
    <arm_group_label>Placebo vehicle</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood Draw&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Stroke survivors within 6 months of clinical presentation for ischemic stroke or TIA event&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with either atherothrombotic, cardioembolic, cryptogenic stroke or TIA&#xD;
             (transient ischemic attack) for whom anticoagulation is not indicated&#xD;
&#xD;
          -  Enrollment in trial must occur within 6 months of clinical presentation for first&#xD;
             stroke or TIA event&#xD;
&#xD;
          -  No history of long-term vitamin E supplement (defined as daily oral tocopherol or&#xD;
             tocotrienol supplementation at least 6mos; within the past 5 years)&#xD;
&#xD;
          -  No current vitamin E supplementation in multi-vitamin&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Disabling stroke ( Modified Rankin Scale &gt; 3)&#xD;
&#xD;
          -  Prior intracranial hemorrhage (excluding traumatic)&#xD;
&#xD;
          -  High risk of bleeding (recurrent gastrointestinal, genitourinary bleeding, active&#xD;
             peptic ulcer disease)&#xD;
&#xD;
          -  Anticipated requirement for long term use of anticoagulation&#xD;
&#xD;
          -  Contraindications to antiplatelet agents (bleeding disorder, thrombocytopenia,&#xD;
             prolonged INR)&#xD;
&#xD;
          -  Irreversible medical condition likely to affect short-term survival or ability to&#xD;
             participate in study such as cancer or other chronic disease with predicted survival&#xD;
             of less than a year or severe psychiatric or neurologic disease that might complicate&#xD;
             evaluation of study outcomes like dementia or schizophrenia&#xD;
&#xD;
          -  Pregnancy or women of child bearing age who are not following an effective method of&#xD;
             contraception&#xD;
&#xD;
          -  Breast feeding&#xD;
&#xD;
          -  Unable or unwilling to provide informed&#xD;
&#xD;
          -  Unlikely to be compliant with therapy or unwilling to return for follow up frequent&#xD;
             clinic visits&#xD;
&#xD;
          -  Concurrent participation in another study with an investigational drug or devise&#xD;
&#xD;
          -  Other likely specific cause of stroke such as dissection, infectious or noninfectious&#xD;
             vasculitis, prothrombotic state&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Carmel Health System</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 9, 2013</study_first_submitted>
  <study_first_submitted_qc>May 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2013</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Andrew Slivka</investigator_full_name>
    <investigator_title>MD, Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Stroke survivors</keyword>
  <keyword>TIA survivors</keyword>
  <keyword>Vitamin E</keyword>
  <keyword>Carotech</keyword>
  <keyword>Tocotrienol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

